<!DOCTYPE html>
<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>DLX1008 (brolucizumab), a single-chain anti-VEGF-A antibody fragment with low picomolar affinity, leads to tumor involution in an in vivo model of Kaposi Sarcoma.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="DLX1008 (brolucizumab), a single-chain anti-VEGF-A antibody fragment with low picomolar affinity, leads to tumor involution in an in vivo model of Kaposi Sarcoma." class="clickable-image" src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224538/bin/pone.0233116.g005.jpg"/> </div> <div class="text-side"> <h1>DLX1008 (brolucizumab), a single-chain anti-VEGF-A antibody fragment with low picomolar affinity, leads to tumor involution in an in vivo model of Kaposi Sarcoma.</h1> <p>Hematoxylin and eosin stains of tumor tissue show morphological differences.H&amp;E stains are of tumor cross-sections. Images are representative of mock scFv control group (A, B) and DLX1008 treatment group (C, D). All scale bars are 100 Î¼m.</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32407363/" target="_blank">32407363</a></p><p>Type: Premalignant/Malignant, Category: Vascular</p>
</div> </div></div></body></html>